Clinical and immunologic analyses of a phase II trial: Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer.

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial – Nature Medicine

News Release: Promising results for chemo-immunotherapy combination against pancreatic cancer, Penn study finds – University of Pennsylvania

Commentary on Twitter

At #ASCO22 Symposium on targeted therapy in GI cancer?

Check out the results & biomarker analysis of the phase 2 PRINCE trial on a CD40 agonist, nivolumab and chemotherapy in #PancreaticCancer, led by speaker @laceykitch @parkerici

Published today ? https://t.co/8aUXuvDHIC

— Nature Medicine (@NatureMedicine) June 3, 2022